• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FMC, Li-Cycle Holdings, Okta And Other Big Stocks Moving Lower On Monday

    10/23/23 11:05:19 AM ET
    $AMAM
    $FMC
    $FNGR
    $FORTY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $AMAM alert in real time by email

    U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session.

    Li-Cycle Holdings Corp. (NYSE:LICY) shares dipped 41% to $1.34 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a comprehensive review of the go-forward strategy for the project.

    Revolution Medicines, Inc. (NASDAQ:RVMD) fell 38% to $17.31 after the company announced it presented clinical activity and safety data from its Phase 1/1b trial of RMC-6236.

    Ambrx Biopharma Inc. (NASDAQ:AMAM) declined 22% to $6.58. Ambrx announced ARX517, a PSMA-targeted ADC, demonstrates 52% PSA50 (≥50% Reduction) and a highly differentiated safety and PK profile in patients with mCRPC, who progressed on multiple FDA-approved treatments.

    FMC Corporation (NYSE:FMC) fell 13.7% to $57.76 after the company updated its third-quarter and FY23 outlook.

    VinFast Auto Ltd. (NASDAQ:VFS) fell 11.4% to $4.76. The company recently entered into a standby equity agreement with YA LL PN for an aggregate subscription amount of up to $1 billion.

    NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) declined 11.4% to $6.25. NewAmsterdam Pharma named Ian Somaiya as Chief Financial Officer.

    FingerMotion, Inc. (NASDAQ:FNGR) fell 8.8% to $5.76.

    YPF Sociedad Anónima (NYSE:YPF) fell 8.5% to $11.24.

    Okta, Inc. (NASDAQ:OKTA) declined 7.6% to $69.85 on continued downward momentum after a threat actor breached its support system and viewed certain customer files. Also, Keybanc maintained an Overweight rating on the stock but lowered its price target from $106 to $95.

    World Acceptance Corporation (NASDAQ:WRLD) fell 6.8% to $103.71 after BMO Capital maintained an Underperform rating on the stock and lowered its price target from $58 to $56.

    Perfect Corp. (NYSE:PERF) fell 6.8% to $2.61.

    Formula Systems (1985) Ltd. (NASDAQ:FORTY) declined 6% to $55.97.

    Now Read This: Hexcel Likely To Report Higher Q3 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $AMAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMAM
    $FMC
    $FNGR
    $FORTY

    CompanyDatePrice TargetRatingAnalyst
    Okta Inc.
    $OKTA
    3/6/2026$97.00Market Perform → Outperform
    BMO Capital Markets
    Okta Inc.
    $OKTA
    3/3/2026$76.00Equal Weight
    Wells Fargo
    Revolution Medicines Inc.
    $RVMD
    2/27/2026$145.00Buy
    UBS
    Okta Inc.
    $OKTA
    2/26/2026$90.00 → $83.00Market Perform
    BMO Capital Markets
    Okta Inc.
    $OKTA
    1/14/2026$120.00Equal-Weight → Overweight
    Stephens
    Okta Inc.
    $OKTA
    12/16/2025$125.00Hold → Buy
    Jefferies
    FMC Corporation
    $FMC
    12/9/2025$13.00Equal Weight → Underweight
    Barclays
    Okta Inc.
    $OKTA
    12/3/2025$112.00 → $90.00Market Perform
    BMO Capital Markets
    More analyst ratings

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Okta with a new price target

    Wells Fargo initiated coverage of Okta with a rating of Equal Weight and set a new price target of $76.00

    3/3/26 8:28:32 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    UBS resumed coverage on Revolution Medicines with a new price target

    UBS resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $145.00

    2/27/26 8:31:41 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BMO Capital Markets reiterated coverage on Okta with a new price target

    BMO Capital Markets reiterated coverage of Okta with a rating of Market Perform and set a new price target of $83.00 from $90.00 previously

    2/26/26 6:48:00 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barry Michael F bought $249,938 worth of shares (18,072 units at $13.83), increasing direct ownership by 1,157% to 19,634 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    3/5/26 12:11:06 PM ET
    $FMC
    Major Chemicals
    Industrials

    Director Leong Yew Poh decreased direct ownership by 6% to 160,000 units (SEC Form 4)

    4 - FingerMotion, Inc. (0001602409) (Issuer)

    12/29/25 6:26:12 AM ET
    $FNGR
    Computer Software: Prepackaged Software
    Technology

    Director Leong Yew Poh decreased direct ownership by 6% to 170,000 units (SEC Form 4)

    4 - FingerMotion, Inc. (0001602409) (Issuer)

    12/8/25 7:08:12 AM ET
    $FNGR
    Computer Software: Prepackaged Software
    Technology

    $AMAM
    $FMC
    $FNGR
    $FORTY
    SEC Filings

    View All

    SEC Form S-8 filed by Okta Inc.

    S-8 - Okta, Inc. (0001660134) (Filer)

    3/5/26 8:09:29 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Okta Inc.

    10-K - Okta, Inc. (0001660134) (Filer)

    3/5/26 8:01:33 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Okta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Okta, Inc. (0001660134) (Filer)

    3/4/26 4:04:44 PM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VINFAST STRUCTURES ITS AUTOMOTIVE PORTFOLIO INTO THREE STRATEGIC BRAND LINES, UNVEILS TWO NEW ULTRA-LUXURY MODELS

    IRVINE, Calif., March 3, 2026 /PRNewswire/ -- VinFast announced the completion of its strategic structuring into three automotive brand lines and officially unveiled two new flagship ultra-luxury models: the Lac Hong 800S and the Lac Hong 900S. The two vehicles join the Lac Hong line - VinFast's ultra-luxury marque - alongside its established VF mass-market passenger vehicle range and Green commercial mobility brand. Under this clearly defined brand structure, Lac Hong represents the pinnacle of ultra-luxury, conceived to honor national pride and currently comprising the 900 LX,

    3/3/26 8:43:00 AM ET
    $VFS
    Auto Manufacturing
    Industrials

    New VinFast VF8 Now Eligible for $5,000 Federal EV Rebate in Canada

    VinFast is proud to announce that the VinFast VF8 is now officially eligible for the Government of Canada's $5,000 federal EVAP rebate, effective February 16, 2026. When combined with other available provincial incentives and credits, Canadian customers can now receive up to $18,000 in total rebates and savings. This makes the VinFast VF8 more accessible than ever, with an all-in MSRP starting from $35,070 after eligible credits. Designed for performance, comfort, and sustainability, the VF8 offers premium electric mobility backed by VinFast's industry-leading 10-year / 200,000 km warranty, setting a new benchmark for peace of mind in EV ownership. "VinFast is committed to acceleratin

    3/2/26 9:20:00 AM ET
    $VFS
    Auto Manufacturing
    Industrials

    FingerMotion Announces Results of Annual Meeting

    Singapore, Singapore--(Newsfile Corp. - March 2, 2026) - FingerMotion Inc. (NASDAQ:FNGR) ("FingerMotion" or the "Company"), a mobile services, data and technology company, announces that, in conjunction with the holding of the Company's recent annual meeting of stockholders on February 26, 2026, the following were the outcome of the matters voted on at the annual meeting:Martin J. Shen, Hsien Loong Wong, Yew Poh Leong, Eng Ho Ng, Tuck Seng Low and Yang Yeat Choe were elected to the Board of Directors of the Company;CT International LLP was appointed as the Company's independent registered public accounting firm;the Company's executive compensation was approved; andthe following executive off

    3/2/26 9:15:00 AM ET
    $FNGR
    Computer Software: Prepackaged Software
    Technology

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barry Michael F bought $249,938 worth of shares (18,072 units at $13.83), increasing direct ownership by 1,157% to 19,634 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    3/5/26 12:11:06 PM ET
    $FMC
    Major Chemicals
    Industrials

    Officer Wang Xiaolin was granted 15,100 shares, increasing direct ownership by 15% to 118,073 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/3/26 9:11:14 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Wei Lin was granted 15,100 shares, increasing direct ownership by 17% to 103,439 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/3/26 9:10:30 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Leadership Updates

    Live Leadership Updates

    View All

    FMC Corporation Announces Election of Michael F. Barry to Board of Directors

    PHILADELPHIA, Feb. 27, 2026 /PRNewswire/ -- FMC Corporation (NYSE:FMC), a leading global agricultural sciences company, today announced the election of Michael F. Barry to the company's Board of Directors, effective February 27, 2026. He will serve on the Audit and Compensation and Human Capital committees.Barry brings more than three decades of global leadership experience in the specialty chemicals industry to FMC's Board. He currently serves as chairman of the Board of Directors of Quaker Houghton and previously served as chief executive officer and president of Quaker Houghton until his retirement in November 2021."We are pleased to welcome Michael to the FMC Board of Directors," said Pi

    2/27/26 4:30:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    FMC Corporation sets 2026 priorities and announces exploration of strategic options including but not limited to the sale of the company

    Company reports 2025 fourth quarter and full year results, provides 2026 outlook  The organization continues to focus on its 2026 operational priorities, including strengthening the balance sheet, improving the competitiveness of its core portfolio, managing its post-patent Rynaxypyr® active strategy and supporting growth of new active ingredientsThe FMC Board of Directors has authorized the exploration of strategic options, including but not limited to, the sale of the company to unlock shareholder value and ensure its growth and core portfolios are best positioned for long-term success PHILADELPHIA, Feb. 4, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced its 2026 prioritie

    2/4/26 5:00:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    Okta Names Rob Bernshteyn and Paul Sagan to Board of Directors

    Okta, Inc. (NASDAQ:OKTA), the leading independent identity partner, today announced the appointment of Rob Bernshteyn and Paul Sagan to the Company's board of directors, effective December 19, 2025. "Rob and Paul bring a wealth of operational experience across SaaS, cybersecurity, and AI that will help drive Okta's next phase of growth," said Todd McKinnon, Okta CEO and Co-Founder. "Their expertise comes at a pivotal moment, as identity becomes the foundation for secure AI. With their leadership, we'll continue strengthening Okta's position as the neutral identity partner and accelerating our work to help customers safely adopt AI agents." "Okta has proven that identity is critical to sec

    12/19/25 4:01:00 PM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Financials

    Live finance-specific insights

    View All

    FMC Corporation Declares Quarterly Dividend

    PHILADELPHIA, Feb. 27, 2026 /PRNewswire/ -- FMC Corporation (NYSE:FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on April 16, 2026, to shareholders of record as of the close of business on March 31, 2026. About FMCFMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protectin

    2/27/26 5:00:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12D mutationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-s

    2/25/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

    REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-prese

    2/18/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $FMC
    $FNGR
    $FORTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care